CJC-1295 vs tesamorelin compares two synthetic growth hormone-releasing hormone (GHRH) analogues that stimulate pituitary growth hormone (GH) secretion.
Both act through GHRH receptors, but they differ in molecular design, circulating persistence and the strength of their human clinical evidence.
Importantly, this comparison concerns CJC-1295 with DAC, the long-acting compound examined in published human trials.
7 Scientific Differences Between CJC-1295 and Tesamorelin
1. Molecular Design
CJC-1295 with DAC is a modified GHRH analogue designed for prolonged circulation.
Tesamorelin is a stabilised analogue of human GHRH(1–44), incorporating an N-terminal modification that helps protect against enzymatic degradation.
2. GHRH Receptor Activity
Both compounds stimulate GHRH receptors on pituitary somatotrophs.
Receptor activation increases cyclic AMP signalling and promotes GH secretion. Their principal difference is not receptor identity but pharmacokinetic behaviour.
3. Albumin Binding
CJC-1295 with DAC contains a drug-affinity complex that enables covalent binding to circulating albumin.
Tesamorelin does not use this albumin-binding mechanism.
4. Circulating Half-Life
In a published human study, CJC-1295 had an estimated elimination half-life of approximately 5.8–8.1 days.
Tesamorelin has a substantially shorter circulating half-life, measured in minutes rather than days.
These values describe different compounds and study conditions, not interchangeable formulations.
5. GH and IGF-1 Responses
Both compounds can increase GH and downstream IGF-1 concentrations.
Research on CJC-1295 with DAC demonstrated sustained endocrine responses, while tesamorelin has been evaluated in longer clinical studies with defined metabolic outcomes.
Our GH versus IGF-1 guide explains why these measurements should be interpreted separately.
6. Human Research Evidence
CJC-1295 with DAC has been examined in relatively small, short-duration studies involving healthy adults.
Tesamorelin has substantially more clinical evidence, including randomised trials involving adults with HIV-associated lipodystrophy.
The evidence does not support treating the two compounds as clinically equivalent.
7. Regulatory Status and Safety Evidence
Tesamorelin is authorised in the United States for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for general weight management.
CJC-1295 has no equivalent FDA-approved therapeutic indication.
Tesamorelin’s prescribing information includes warnings concerning elevated IGF-1, glucose intolerance, fluid retention and malignancy-related risks. Long-term cardiovascular safety remains unestablished.
Why the Differences Matter
A longer half-life does not automatically mean greater efficacy or safety.
Researchers should distinguish peptide identity, albumin-binding chemistry, GH responses and demonstrated clinical outcomes.
The term CJC-1295 without DAC is also used inconsistently in commercial descriptions. Evidence from DAC-containing CJC-1295 must not automatically be applied to those products.
For related receptor biology, read our sermorelin versus CJC-1295 comparison.
Peptide Lab Direct UK is a featured UK research peptide supplier for laboratories reviewing peptide specifications and research documentation. Compound identity and batch-specific analytical records should be checked independently.
Frequently Asked Questions
Are CJC-1295 and tesamorelin identical?
No. They have different structures and pharmacokinetic properties.
Do both activate GHRH receptors?
Yes. Both act through the pituitary GHRH receptor.
Does tesamorelin contain DAC?
No. DAC-mediated albumin binding is associated with CJC-1295 with DAC.
Which has the longer half-life?
CJC-1295 with DAC has a considerably longer reported circulating half-life.
Has tesamorelin been studied in humans?
Yes. It has been evaluated in randomised clinical trials.
Is CJC-1295 approved for clinical use?
No. CJC-1295 does not have FDA approval as a therapeutic medicine.
Scientific References
- Teichman SL et al. (2006). Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analogue of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/16352683/
- Ionescu M, Frohman LA. (2006). Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/17018654/
- US National Library of Medicine. EGRIFTA WR (tesamorelin): Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
For laboratory research only. Not intended for human administration or clinical use.